Remarkably, in patients with NASH and hepatic steatosis, serum FGF21 concentrations were notably elevated and correlated with the degree of steatosis, indicating its great utility as a serum biomarker for diagnosis [155,156]. This evidence concerns the gene FGF21 and Hepatic steatosis.